Loading...
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Dreyling, M Morschhauser, F Bouabdallah, K Bron, D Cunningham, D Assouline, S Verhoef, G Linton, Kim M Thieblemont, C Vitolo, U
Dreyling, M
Morschhauser, F
Bouabdallah, K
Bron, D
Cunningham, D
Assouline, S
Verhoef, G
Linton, Kim M
Thieblemont, C
Vitolo, U
Citations
Altmetric:
Abstract
Copanlisib is a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant activity against the α- and δ- isoforms.
Description
Date
2017-06-14
Publisher
Collections
Keywords
Type
Article
Citation
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. 2017 Ann Oncol